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Characteristics and Risk Factors of Oxaliplatin-related
Hypersensitivity Reactions
Yu-Yun Shao,1,5 Fu-Chang Hu,2 Jin-Tung Liang,3 Wen-Tzu Chiu,1 Ann-Lii Cheng,1,4 Chih-Hsin Yang1*
Background/Purpose: Hypersensitivity reactions during oxaliplatin infusion are a major problem associ-
ated with its use. In this study, we investigated the characteristics and risk factors of these events.
Methods: All patients who had received oxaliplatin in outpatient settings from January 2006 to March 2007
in a medical center were enrolled in this retrospective study. All the oxaliplatin infusions were reviewed. Manifes-
tations of hypersensitivity reactions and clinicopathological variables were collected from medical records.
Results: Three hundred and eighty-three patients with 3648 oxaliplatin infusions were reviewed. Forty-
seven patients (12.7%) developed hypersensitivity reactions, which occurred after a median of 10 infu-
sions. The median time of onset from start of infusion was 40 minutes. Most presentations (90.7%) were
mild to moderate, but rechallenge with oxaliplatin led to a high chance of further reactions (71.4%).
Cutaneous symptoms were the most prevalent manifestation, followed by respiratory symptoms. With
each repeated infusion, the incidence of hypersensitivity reactions increased. Higher oxaliplatin dose per
infusion was an independent risk factor for such reactions.
Conclusion: Patients treated with oxaliplatin for an extended period have a greater risk of oxaliplatin-
related hypersensitivity reactions.
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Oxaliplatin has been used extensively worldwide
for treating colorectal cancer and other malig-
nancies. However, hypersensitivity reactions to
oxaliplatin are a major problem. Although the in-
cidence rate has been found to be < 2% in earlier
studies,1,2 recent reports have shown occurrence
rates as high as 10–25%.3–7 The risk factors remain
unclear, and only one study has explored this issue
by multivariate analysis.7
The unpredictability of hypersensitivity reac-
tions deserves attention because they can interfere
with the administration of chemotherapy and can
be life-threatening.8 Steroids are frequently applied
as premedication to prevent emesis, but they are
not always effective in preventing oxaliplatin-
related hypersensitivity reactions.9,10 The benefits
of applying antihistamines and/or prolonging
infusion time are also controversial.11,12
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In this retrospective study, we analyzed the
incidence, severity, and risk factors of hypersensi-
tivity reactions to oxaliplatin. The effects of pre-
medication or prolongation of infusion time on
prevention of reactions were examined.
Materials and Methods
Patients and study protocol
We searched the database of the Department of
Pharmacy, National Taiwan University Hospital.
All patients who had received at least one dose of
oxaliplatin at an outpatient department during
the period from January 2006 to March 2007
were enrolled. Medical records during oxaliplatin
infusion were reviewed. Hypersensitivity reactions
were classified into hypertension, fever, chills, neu-
ropathy, and cutaneous, respiratory and digestive
symptoms. The above events were excluded if they
were clearly documented to be caused by condi-
tions other than hypersensitivity reactions, such
as infection or disease progression. The severity of
these reactions was evaluated according to Com-
mon Terminology Criteria for Adverse Events ver-
sion 3.0.13 In addition, data on sex, age, type of
malignancy, dose of oxaliplatin administered, total
number of oxaliplatin courses, premedication, and
purpose of chemotherapy (adjuvant, neoadjuvant
or palliative therapy) was collected. This study was
approved by the Research Ethics Committee of
the National Taiwan University Hospital.
Statistical methods
Statistical analyses were performed with SAS ver-
sion 9.1.3 (SAS Institute, Cary, NC, USA) and R sta-
tistical software (Free Software Foundation Inc.,
Boston, MA, USA). In statistical testing, two-sided
p values ≤ 0.05 were considered statistically signif-
icant. The clinicopathological variables potentially
associated with the development of hypersensi-
tivity reactions to oxaliplatin were collected and
subjected to univariate and multivariate analyses.
These variables included: sex; age; diagnosis; pre-
medication with granisetron, diphenhydramine, ra-
nitidine or dexamethasone; and dose and infusion
time of oxaliplatin. Cox’s proportional hazards
model was used to estimate the effects of these
potential predictors on the number of infusions or
the actual time to the first hypersensitivity reaction.
The goal of regression analysis is to find parsi-
monious regression models that fit well with the
observed data. To ensure the quality of the regres-
sion analysis results, the basic model-fitting tech-
niques for (1) variable selection; (2) goodness-of-fit
(GOF) assessment; and (3) regression diagnostics
were used. Specifically, in the stepwise variable se-
lection procedure, all the significant univariates and
non-significant covariates were considered, and
the significance levels for entry and for stay were
set to ≥ 0.15. The adjusted generalized R2 and the
Grønnesby–Borgan GOF test were used to assess
the GOF of the fitted Cox’s proportional hazards
model. However, the value of the adjusted gener-
alized R2 for Cox’s proportional hazards model is
known to be low. A larger p value of the Grønnesby–
Borgan GOF test indicates a better fit. The statistical
tools for regression diagnostics, such as verifica-
tion of proportional hazards assumption, residual
analysis, detection of influential cases, and check
for multicollinearity, were applied to discover
model or data problems.
The Nelson–Aalen estimate of the cumulative
hazard rate for the number of infusions to the first
hypersensitivity reaction was plotted. The signifi-
cant variables discovered in the final Cox’s propor-
tional hazards model were used for stratification.
The result was further fitted by a non-parametrically
smoothed curve using the locally weighted scatter-
plot smoothing method to check for its linearity
against the number of infusions. The rationale be-
hind this examination was that, if the occurrence
of hypersensitivity reactions associated with each
infusion was purely an independent event, then the
smoothed curve should have been in a linear form
that indicated a constant hazard rate.
Results
A total of 383 patients were enrolled in this study,
and a total of 3648 oxaliplatin infusions were
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recorded. Their basic characteristics are listed in
Table 1. Patients received a median of eight infu-
sions, and a mean 87.8mg/m2 oxaliplatin per infu-
sion. Oxaliplatin was given as a biweekly regimen in
73.4% of patients. About 87.5% of the patients had
colorectal cancer, and about half of them received
oxaliplatin for palliative therapy. Forty-seven pa-
tients had hypersensitivity reactions to oxaliplatin,
for a prevalence rate of 12.3%. The first reactions
developed after a median of 10 infusions of oxali-
platin (range, 2–19). Most patients (85%) had their
first reactions after the sixth course (Figure 1A).
The median time of onset from start of infusion was
40 minutes, and most reactions (88.7%) occurred
within the first 2 hours (Figure 1B).
To examine the potential risk factors for devel-
opment of hypersensitivity reactions, the afore-
mentioned clinicopathological variables were put
into univariate and then multivariate analyses
(Tables 2 and 3). Although no variables were sig-
nificant in univariate analysis, multivariate analy-
sis by Cox’s proportional hazards model revealed
that oxaliplatin infusion dose and premedica-
tion with 5 mg dexamethasone were significantly
associated with hypersensitivity reactions during
earlier infusions. The result was very similar when
analyzed with the actual time from the first infu-
sion to the first reaction as the endpoint, although
Table 1. Patient characteristics (n = 383)*
Age (yr) 61 (21–91)
Sex, male 204 (53.3)
Total infusion courses* 8 (1–56)
Oxaliplatin interval*
Weekly 39 (10.2)
Biweekly 281 (73.4)
Triweekly 56 (14.6)
Oxaliplatin dose (mg/m2)† 87.8 (85.9–89.7)
Infusion time (min)† 121 (119–122)
Premedication
Granisetron 382 (99.7)
Diphenhydramine 30 (7.8)
Ranitidine 15 (3.9)
Dexamethasone (mg)
Nil 28 (7.3)
5 139 (36.3)
≥ 10 216 (56.4)
Type of cancer
Colorectal cancer 335 (87.5)
Pancreatic cancer 13 (3.4)
Biliary tract cancer 7 (1.8)
Gastric cancer 20 (5.2)
Others‡ 8 (2.0)
Purpose of chemotherapy§
Total 335 (100)
Palliative 174 (51.9)
Adjuvant 126 (37.6)
Neoadjuvant 35 (10.4)
*Data presented as median (range) or n (%); †data presented as
mean (95% confidence interval); ‡hepatocellular, nasopharyngeal,
ovarian, esophageal and jejunal carcinoma; §for colorectal cancer
patients. CI= confidence interval.
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Figure 1. (A) The number of patients who developed their
first hypersensitivity reaction during oxaliplatin infusion.
(B) Cumulative incidence of hypersensitivity reactions from
the start of oxaliplatin infusion.
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the two factors became only of borderline signif-
icance. Only 7% of patients did not receive steroids
as premedication (Table 1), therefore, the result
with 5mg dexamethasone as a risk factor mainly re-
flected its comparison with ≥10mg dexamethasone.
Stratified by the two significant variables among
the whole patient group, the Nelson–Aalen estima-
tor plot demonstrated the cumulative hazards dur-
ing each infusion (Figure 2). The locally weighted
scatterplot smoothing method was used to fit the
curves to facilitate judgment of linearity. The plots
were clearly not simply linear. This demonstrated
that oxaliplatin-related hypersensitivity reactions
did have an increased incidence with each re-
peated infusion.
Eighty-six episodes of hypersensitivity reac-
tions were recorded. During the first reactions,
cutaneous symptoms were the most prevalent
manifestation (70.9%, Table 4), followed by res-
piratory symptoms (30.3%) and fever (25.5%).
Table 2. Univariate analysis of risk factors for hypersensitivity reaction by Cox’s proportional hazards models
using a hazard ratio
Earlier infusion numbers Shorter time 
Variables to the first HSR to the first HSR
HR p HR p
Sex, male 1.425 0.230 1.171 0.590
Age 1.004 0.750 1.015 0.215
Diagnosis (vs. CRC)
Pancreatic cancer 4.252 0.052 1.362 0.669
Biliary tract cancer 2.276 0.418 1.302 0.794
Gastric cancer 0.440 0.417 0.380 0.338
Oxaliplatin dose 1.007 0.154 1.005 0.292
Infusion time 0.995 0.652 0.989 0.285
Premedication
Granisetron 20.17 0.926 20.18 0.813
Diphenhydramine 1.623 0.270 1.968 0.122
Ranitidine 2.669 0.104 3.921 0.177
Dexamethasone 3.492 0.216 2.192 0.192
HR = Hazard ratio; CRC = colorectal cancer; HSR = hypersensitivity reaction.
Table 3. Multivariate analysis of risk factors for hypersensitivity reaction by Cox’s proportional hazards
models using a hazard ratio
Covariate
Parameter Standard Wald’s 
p HR (95% CI)
estimate error χ2 test
1. Earlier infusion numbers to the first hypersensitivity reaction
Premedication with 0.739 0.310 5.691 0.017 2.094 (1.141–3.843)
5 mg dexamethasone
Oxaliplatin dose 0.023 0.008 8.210 0.004 1.024 (1.007–1.040)
2. Shorter time to the first hypersensitivity reaction
Premedication with 0.558 0.298 3.495 0.062 1.747 (0.973–3.135)
5 mg dexamethasone
Oxaliplatin dose 0.013 0.008 2.758 0.097 1.013 (0.998–1.028)
HR = Hazard ratios; CI = confidence interval.
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Most of the reactions were mild. Over ninety per-
cent were grade 1 or 2 reactions. Nonetheless, one
patient died of anaphylactic shock during his
fourth oxaliplatin infusion. There had been no
discomfort during the previous three infusions.
A review of the other seven events with grade 3/4
toxicity showed that only three were preceded by
prior mild episodes.
After hypersensitivity reactions, 35 patients 
received rechallenge with a mean 4.5 infusions.
Twenty-five of these (71.4%) developed subse-
quent events. Three patients had oxaliplatin in-
fusion prolonged to 4 hours, but all developed
hypersensitivity reactions. The manifestations and
severity of these reactions were generally similar
to the first episodes.
Discussion
We here present a retrospective study on oxali-
platin-related hypersensitivity reactions. The oc-
currence rate of hypersensitivity reactions was
12.3% and they developed after a median of 10
courses. These results were consistent with previ-
ous studies.3–7,10 The onset after the start of infu-
sion varied, ranging from within 15 minutes to
20 hours later.4,14 In our study, about 90% of pa-
tients had symptoms within the first 2 hours.
Oxaliplatin was mostly applied in a 2-hour infu-
sion, which implied that most reactions occurred
during infusion.
Several limitations of this study should be
noted. Hypersensitivity symptoms were not actively
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Figure 2. Nelson–Aalen estimates of cumulative hazard rates for the number of infusions to the development of the first
hypersensitivity reaction, stratified by the two statistically significant risk factors. The first and third quartiles of oxaliplatin
doses per body surface area were chosen for illustrative purposes. The smoothed curves (the smoothed dashed lines)
were plotted by using the locally weighted scatterplot smoothing method in the free R software, which uses locally-
weighted polynomial regression with smooth span (f) = 2/3 to check for its linearity against the number of infusions.
Table 4. Manifestations of the hypersensitivity
reactions (n = 47)
Symptom
Cutaneous 61 (70.9)
Respiratory symptoms 26 (30.3)
Fever 22 (25.5)
Hypertension 16 (18.6)
Chills 16 (18.6)
Peripheral neuropathy 12 (14.0)
Digestive symptoms 17 (19.8)
Consciousness change 3 (3.5)
Grade
1–2 78 (90.7)
3–5 8 (9.3)
Onset (min) 40 (5–215)
*Data presented as n (%) or median (range).
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pursued, therefore, mild discomforts and delayed
reactions after departure from hospital might have
been ignored or forgotten. Frail or completely bed-
ridden patients who never received chemother-
apy in an outpatient setting were not enrolled.
Therefore, the incidence of hypersensitivity reac-
tions in this study was likely to have been under-
estimated. Besides, the application interval of
oxaliplatin was diverse. However, multivariate
analyses demonstrated similar results regardless
of whether the endpoints were infusion numbers
or actual time from start of infusion.
Hypersensitivity reactions related to oxaliplatin,
unlike taxanes, usually developed after repeated
exposure. However, this observation could have
been merely a presentation of cumulative inci-
dence of independent events because more expo-
sure might have led to a greater risk of reaction. By
plotting cumulative hazards, we actually demon-
strated that repeated infusions did indeed result
in a higher risk of reaction. Other platinum com-
pounds, such as cisplatin, also cause similar reac-
tions after repeated exposure.15,16 One of the first
described hypersensitivity reactions occurred in 
a 15-year-old boy during the eighth infusion.17
Likewise, the highest incidence of hypersensitiv-
ity to carboplatin occurred at approximately the
eighth cycle.18 These findings indicate that hyper-
sensitivity to platinum complexes is prone to de-
velop after multiple uncomplicated courses.
Other than repeated infusion as a risk factor,
we found that higher infusion doses were associ-
ated with earlier reactions, which has not been
reported before. The other significant risk factor
was the premedication with 5 mg dexametha-
sone. Very few patients did not receive steroids;
therefore, this result mainly compared 5 mg with
≥ 10 mg dexamethasone. However, when we com-
pared patients with 5 mg and ≥ 10 mg dexam-
ethasone only, the result became non-significant.
Therefore, whether higher doses of steroid do
have a protective effect remains to be elucidated.
A previous study that explored risk factors 
for oxaliplatin-related hypersensitivity reactions
found younger age, female sex, and salvage ther-
apy to be predictors for reactions.7 These variables
were not significant in our study. One reason is
the ethnic differences between the participants in
this study and the other study, and the other pos-
sibility is that the two predictors, the doses of ox-
aliplatin and dexamethasone, in our study were
not analyzed in the earlier study.
Thirty-four of our patients elected to receive
oxaliplatin again after prior hypersensitivity re-
actions. The occurrence rate of adverse reactions
surged to 71.4%, which was much higher than
the previously reported 29–50%.4,10,12 Prior stud-
ies had limited patient numbers and fewer rechal-
lenges, but our patients received 4.5 additional
infusions on average. The increased exposure could
explain the high rate of occurrence of hypersensi-
tivity. Some desensitization protocols have had
success with expanding the infusion time to 24
hours.19–23 Three of our patients had 4-hour in-
fusions during rechallenge, but all three failed re-
challenge and developed hypersensitivity reactions.
In conclusion, repeated oxaliplatin infusion ac-
tually increased the chances of oxaliplatin-related
hypersensitivity reactions. Rechallenge could lead
to a high prevalence of further episodes.
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